Pacific Biosciences Of California (PACB) Cost of Revenue (2011 - 2026)

Pacific Biosciences Of California's Cost of Revenue history runs 16 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 36.83% year-over-year to $24.3 million in Q1 2026; TTM through Mar 2026 was $100.0 million, a 21.68% decrease from a year earlier, with the FY2025 full-year figure at $114.2 million, down 2.15% from the prior year.
• Cost of Revenue retreated to $24.3 million in Q1 2026 per PACB's latest filing, from $28.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $48.8 million in Q4 2023 and bottomed at $18.8 million in Q3 2022.
• The 5-year median for Cost of Revenue is $28.1 million (2025), against an average of $28.4 million.
• Biggest YoY gain for Cost of Revenue was 472.31% in 2022; the steepest drop was 63.48% in 2022.
• Year by year, Cost of Revenue stood at $22.2 million in 2022, then jumped by 119.63% to $48.8 million in 2023, then sank by 40.22% to $29.2 million in 2024, then retreated by 3.73% to $28.1 million in 2025, then fell by 13.33% to $24.3 million in 2026.
• Per Business Quant, the three latest PACB Cost of Revenue figures stand at $24.3 million (Q1 2026), $28.1 million (Q4 2025), and $22.5 million (Q3 2025).